Terms ending in 2036
Every in-force patent on Cellectis's record whose computed term ends in 2036, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,959,091 | Methods for Engineering T Cells for Immunotherapy by Using RNA-Guided Cas Nuclease System In force · Medium confidence | Cellectis | In force | Medium confidence | |
| US 10,752,684 | ROR1 (NTRKR1) Specific Chimeric Antigen Receptors for Cancer Immunotherapy In force · High confidence | Cellectis | In force | High confidence | |
| US 10,759,868 | Trophoblast Glycoprotein (5T4, TPBG) Specific Chimeric Antigen Receptors for Cancer Immunotherapy In force · High confidence | Cellectis | In force | High confidence | |
| US 11,692,169 | Cells for Immunotherapy Engineered for Targeting Antigen Present Both on Immune Cells and Pathological Cells In force · Medium confidence | Cellectis | In force | Medium confidence | |
| US 10,294,304 | Chimeric Antigen Receptors Targeting B-Cell Maturation Antigen In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 10,837,024 | Modifying Messenger RNA Stability in Plant Transformations In force · High confidence | Cellectis | In force | High confidence | |
| US 11,072,644 | Inhibitory Chimeric Antigen Receptors In force · High confidence | Allogene Therapeutics, Inc. | In force | High confidence | |
| US 11,312,782 | Chimeric Antigen Receptors Targeting B-Cell Maturation Antigen In force · High confidence | Pfizer Inc. | In force | High confidence | |
| US 10,472,613 | Method for Modulating Car-Induced Immune Cells Activity In force · High confidence | Cellectis | In force | High confidence | |
| US 12,774,451 | Methods for Improving Functionality in NK Cell by Gene Inactivation Using Specific Endonuclease In force · High confidence | Cellectis | In force | High confidence | |
| 4 more term ends in 2036 · Pro | |||||
10 of 14 patents shown. Soonest term end first, then patent number.
Pro members see all 14.
10 of these are in force and held by Cellectis.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.